El interés en corto de Jin Medical International da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Jin Medical International. Los datos de interés en corto se actualizan cada dos semanas.

Jin Medical International (NASDAQ:ZJYL) Bolsa, Informe de interés en corto

Jin Medical International

Jin Medical International Ltd offers rehabilitation equipment. It is primarily engaged in the design, development, manufacturing, and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's products are sold to distributors in both China and in overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, nursing products, and conlo products.

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International Ltd

For the first time in three years, capital raises in the <a href="https://www.benzinga.com/cannabis">cannabis sector increased,</a> according to Frank Colombo, managing director of data analytics and investment banking at Viridian Capital Advisors. 
Colombo provided an overview of capital raising trends in the space on Tuesday at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>. He told the crowd gathered in Chicago there's been an increase of 14.8% in capital raises in 2024, driven mostly by Canadian equities and U.S. debt.
Colombo said U.S. debt accounts for over 50% of capital raises, indicating a reliance on debt financing rather than equity in the market. Out of all sectors, retail and cultivation sectors are responsible for half of all capital raises. However, out of 12 different sectors, "investments in M&amp;A&#8221; were "really up," he said.
Colombo, along with Scott Greiper, founder and president of Viridian Capital Advisors, gave a presentation discussing the core principles of equity research and investment strategies tailored for the cannabis sector.
Colombo said the U.S. cultivation and retail sectors saw a significant 226% increase in capital raises year-to-date, primarily driven by debt refinancing rather than new capital influx. "Out of the $830 million of new debt, it&#8217;s only been like $120 of new money," he said, adding that many cannabis multi-state operators (MSOs) are overleveraged.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41237666/exclusive-tax-changes-could-unlock-hundreds-of-millions-in-cash-flow-for-cannabis-sector-experts">EXCLUSIVE: Tax Changes Could Unlock &#8216;Hundreds Of Millions In Cash Flow&#8217; For Cannabis Sector, Experts Predict</a>
<h3 class="wp-block-heading">Credit Analysis Is Of Utmost Importance</h3>
Colombo also emphasized the importance of nuanced credit analysis, recommending a laddered approach to equity investment that avoids high-risk entities while targeting those with strong credit ratings and growth potential. "You should, really, stick primarily to a company that we rate as the better credits, the top 10 out of the 30 we rate every week," Colombo said, referring to Viridian's analyses.
"For the near term, we think that the most appropriate equity stance to be in is don&#8217;t step in the proverbial dog s&#x2A;&#x2A;t," Colombo said. "Credit problems have been a big part of the equity, downturn" for a lot of cannabis operators, "so you just need to avoid disasters, and if you can do that, you&#8217;re going to get the rising of all boats."
Lastly, he said market catalysts in 2025 such as potential cannabis rescheduling and banking reform, could allow companies to improve their financial positions and attract new investments. "Pay close attention to credit analysis… As these catalysts start to happen."
That said, Greiper explained that Viridian provides insights into where capital is flowing, the types of investors involved, and how valuations are determined.
"We&#8217;re nine and a half years into this,&#8221; Greiper said. "We&#8217;ve covered about 75 billion dollars in deals and about 6500 transactions."
After joining the firm four years ago, Colombo took Viridian's work to the next level. The company continually evolves its data offerings, including a subscription model allowing historical trend analysis and deeper insights into market activity.
"We put out our market reports every day," Greiper said. &#8220;We&#8217;ve invested in our people, we&#8217;ve invested in our analysts because tracking every deal in the cannabis industry globally is really a lot of fun.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a></li>
</ul>
Frank Colombo, of Viridian Capital Advisors, speaks at the Benzinga Cannabis Capital Conference on Tuesday. Photo by Wendy Davis.

Cannabis

News

Entrepreneurship

Financing

Events

Exclusives

EXCLUSIVE: Tracking Every Cannabis Deal Is 'A Lot Of Fun,' Says Financial Expert Behind Essential Investor Tool

GigaCloud Tech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NYSE">GCT</a>) short percent of float has risen 18.12% since its last report. The company recently reported that it has 6.90 million shares sold short, which is 36.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GigaCloud Tech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674124_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GigaCloud Tech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing GigaCloud Tech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GigaCloud Tech's peer group average for short interest as a percentage of float is 4.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About GigaCloud Tech?

Atlassian's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NYSE">TEAM</a>) short percent of float has risen 14.21% since its last report. The company recently reported that it has 3.33 million shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Atlassian Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674119_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Atlassian has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Atlassian's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Atlassian's peer group average for short interest as a percentage of float is 3.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TEAM

How Is The Market Feeling About Atlassian?

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has risen 15.79% since its last report. The company recently reported that it has 6.71 million shares sold short, which is 3.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674114_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zimmer Biomet Holdings's Recent Short Interest

Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading higher today. Here&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41257193/boeings-october-deliveries-expected-to-plummet-amid-strike-challenges-analyst">what you need to know.</a>
What To Know: A report from the U.S. Transportation Department's Office of Inspector General raised serious concerns about the FAA's oversight of Boeing's production processes. The report, commissioned by Congress, highlighted that the FAA's monitoring of Boeing's manufacturing, particularly for the 737 and 787 models, is ineffective and often reactive rather than proactive. The Office of Inspector General criticized the FAA for failing to implement a more data-driven oversight approach and pointed out unresolved safety issues. It also raised concerns about Boeing employees acting on behalf of the FAA in certain cases.
Following a fuselage panel incident on a 737 Max aircraft in January 2024, Boeing addressed safety concerns and revamped its manufacturing processes. These include internal safety reforms and new leadership, with a new CEO taking over to rebuild trust with regulators and the public. The report provided 16 recommendations for improving Boeing's compliance with FAA standards, which are set to be implemented between 2025 and 2028.
Senator Tammy Duckworth, chair of the Senate&#8217;s aviation safety subcommittee, criticized the FAA for not holding Boeing accountable and emphasized the need for stronger oversight. She pledged continued Congressional monitoring to ensure that Boeing and the FAA prioritize public safety.
Meanwhile, Boeing faces additional challenges with a four-week strike by the International Association of Machinists and Aerospace Workers, which has halted production at key facilities. The strike, involving about 33,000 workers, is expected to cost the company over $1 billion per month. Boeing has filed an unfair labor practice charge against the union, accusing it of bad faith bargaining, while the union claims Boeing is unwilling to negotiate on key issues related to wages and working conditions. The conflict remains unresolved.
Financial Metrics: The company reported a net income loss of $1.439 billion for the year, with loss EPS of $2.33. Despite revenue growth of 16.79%, Boeing continues to operate at a loss and its EBITDA margin stands at -2.40%, indicating ongoing operational difficulties. Boeing&#8217;s long-term debt is substantial at $53.162 billion and the company's enterprise value is $135.657 billion. 
BA Price Action: Boeing shares were up by 2.35% at $150.04 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-1024x537.png" alt="" class="wp-image-591869" style="width:478px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1.png 1084w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41278449/why-texas-instruments-could-beat-earnings-estimates-again">Why Texas Instruments Could Beat Earnings Estimates Again</a></li>
</ul>
Photo via Shutterstock.

Movers

Boeing Company Shares Are Trading Higher Today: What's Going On

Citigroup analyst Jon Tower maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Neutral and lowers the price target from $450 to $440.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Domino's Pizza, Lowers Price Target to $440

Politics

General

CNN To Host Town Hall With Kamala Harris On October 23

HC Wainwright &amp; Co. analyst Edward White maintains Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) with a Buy and lowers the price target from $18 to $17.

NYXH

HC Wainwright & Co. Maintains Buy on Nyxoah, Lowers Price Target to $17

BlackRock Finance&nbsp;came out with quarterly earnings of $11.46 per share, beating the Zacks Consensus Estimate of $10.42 per share. This compares to earnings of $10.91 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 9.98%. A quarter ago, it was expected that this investment firm would post earnings of $9.96 per share when it actually produced earnings of $10.36, delivering a surprise of 4.02%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
BlackRock Finance, which belongs to the Zacks Financial - Investment Management industry, posted revenues of $5.2 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.93%. This compares to year-ago revenues of $4.52 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
BlackRock Finance shares have added about 17.7% since the beginning of the year versus the S&amp;P 500&#39;s gain of 21.2%.
<h2>What&#39;s Next for BlackRock Finance?</h2>
While BlackRock Finance has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for BlackRock Finance: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $11.14 on $5.56 billion in revenues for the coming quarter and $41.83 on $20.1 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Investment Management is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, SEI Investments (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seic#NASDAQ">SEIC</a>), has yet to report results for the quarter ended September 2024.
This investment management firm is expected to post quarterly earnings of $1.07 per share in its upcoming report, which represents a year-over-year change of +23%. The consensus EPS estimate for the quarter has been revised 2% higher over the last 30 days to the current level.
SEI Investments&#39; revenues are expected to be $532.11 million, up 11.6% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2349134/blackrock-finance-blk-surpasses-q3-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2349134">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Mid Cap

Management

Markets

SEIC

BlackRock Finance Surpasses Q3 Earnings and Revenue Estimates

TD Cowen analyst Doug Creutz maintains Sony Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) with a Buy, adjusts target to $23 from $107 (5-1 Stock Split).

Sony Group Corporation American Depositary Shares

SONY

TD Cowen Maintains Buy on Sony Gr, Adjusts Price Target To $23 (5-1 Stock Split)

Barclays analyst Jeffrey Bernstein maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Underweight and lowers the price target from $380 to $370.

Barclays Maintains Underweight on Domino's Pizza, Lowers Price Target to $370

Jefferies analyst Alexander Slagle maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Hold and lowers the price target from $455 to $450.

Jefferies Maintains Hold on Domino's Pizza, Lowers Price Target to $450

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Reiteration

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target

Over the past 24 hours, Lido Staked Ether's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">STETH</a>) price has risen 3.92% to $2,444.64. This continues its positive trend over the past week where it has experienced a 1.0% gain, moving from $2,428.48 to its current price. As it stands right now, the coin's all-time high is $4,829.57. 
The chart below compares the price movement and volatility for Lido Staked Ether over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728673422_0.png" alt="price_chart" />
The trading volume for the coin has fallen 41.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 1.13%. This brings the circulating supply to 9.72 million. According to our data, the current market cap ranking for STETH is #8 at $23.76 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728673422_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$STETH

Lido Staked Ether's Price Increased More Than 3% Within 24 hours

Charles Schwab Corporation Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) shares are trading higher by 1.48% to $67.64 during Friday&#8217;s session amid strength in the <a href="https://www.benzinga.com/news/earnings/24/10/41293190/us-banks-top-q3-earnings-estimates-jpmorgan-delivers-robust-beat-financial-sector-stocks-hit-record">U.S. financial sector</a> following a series of strong third-quarter earnings reports from major institutions, including JPMorgan Chase, Wells Fargo and BlackRock.
These financial heavyweights surpassed earnings expectations, which lifted the entire sector and sparked a rally in peer financial firms like Charles Schwab.
What&#8217;s Going On: The Financial Select Sector SPDR Fund (XLF) jumped nearly 2%, hitting record highs and setting the stage for a broad-based rally across financial stocks. This momentum has had a direct impact on Schwab, with investors betting that the brokerage giant will deliver strong earnings, driven by rising interest income and solid client activity.
As a leading brokerage and wealth management firm, Charles Schwab has benefited from an ongoing shift toward self-directed investing and increasing demand for financial advice. 
In recent quarters, Schwab has also capitalized on the higher interest rate environment, which has boosted net interest margin—an area that has been a strong focus for the financial industry this earnings season. 
JPMorgan Chase, for example, beat estimates with $23.53 billion in net interest income (NII), signaling strength in this critical area of revenue generation.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41290382/producer-inflation-rises-more-than-expected-in-september-as-food-transportation-c">Producer Inflation Rises More Than Expected In September As Food, Transportation Costs Jump</a>
What Else: With interest rates remaining elevated, Schwab's NII is expected to be a key driver of its upcoming earnings. Like JPMorgan and Wells Fargo, Schwab is poised to see continued benefit from the higher rate environment as it earns interest on client cash balances held in sweep accounts. 
This could offset any potential weakness in other areas, such as asset management fees, which may be pressured by market volatility.
Charles Schwab's business model is well-diversified, spanning brokerage, banking, and wealth management services, allowing it to capture growth across different segments. The bank's focus on low-cost trading, investment advisory services, and a broad range of financial products gives it a competitive advantage in attracting retail and institutional clients. 
In addition, Schwab's vast network of individual retirement accounts (IRAs) and retail brokerage accounts positions it well to benefit from the long-term shift toward self-directed retirement savings.
Read Also: <a href="https://www.benzinga.com/news/24/10/41288103/elon-musks-fully-autonomous-driving-dreams-now-scheduled-for-2025-but-regulatory-hurdles-stand-in-th">Elon Musk&#8217;s Fully Autonomous Driving Dreams Now Scheduled For 2025, But Regulatory Hurdles Stand In The Way Of Tesla&#8217;s Robotaxi Rollout</a>
<h2 class="wp-block-heading">How To Buy SCHW Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Charles Schwab&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SCHW has a 52-week high of $79.49 and a 52-week low of $48.66.

SCHW

Why Charles Schwab (SCHW) Stock Is Rising

Over the past 24 hours, Wrapped Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WBTC</a>) price rose 5.82% to $62,780.00. This continues its positive trend over the past week where it has experienced a 1.0% gain, moving from $62,216.56 to its current price. As it stands right now, the coin's all-time high is $73,505.00. 
The chart below compares the price movement and volatility for Wrapped Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728673353_0.png" alt="price_chart" />
The trading volume for the coin has risen 2.0% over the past week diverging from the circulating supply of the coin, which has decreased 1.08%. This brings the circulating supply to 149 thousand, which makes up an estimated 100.0% of its max supply of 149 thousand. According to our data, the current market cap ranking for WBTC is #16 at $9.40 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728673353_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WBTC

Wrapped Bitcoin Up More Than 5% In 24 hours

Over the past 24 hours, WETH's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WETH</a>) price rose 4.25% to $2,446.74. This continues its positive trend over the past week where it has experienced a 1.0% gain, moving from $2,429.32 to its current price. As it stands right now, the coin's all-time high is $4,799.89. 
The chart below compares the price movement and volatility for WETH over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728673343_0.png" alt="price_chart" />
WETH's trading volume has climbed 4.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.08%. This brings the circulating supply to 2.96 million. According to our data, the current market cap ranking for WETH is #17 at $7.24 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728673343_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WETH

WETH's Price Increased More Than 4% Within 24 hours

5 analysts have shared their evaluations of Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Tanger, presenting an average target of $31.8, a high estimate of $35.00, and a low estimate of $29.00. This current average reflects an increase of 7.43% from the previous average price target of $29.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1728673292_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tanger. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Spector</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Samir Khanal</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Samir Khanal</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tanger. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tanger compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Tanger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Tanger's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SKT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tanger analyst ratings.</a>
<h2>About Tanger</h2>
Tanger Inc is a leading owner and operator of outlet and open-air retail shopping destinations. Tanger's portfolio of 38 outlet centers and one open-air lifestyle center comprises over 15 million square feet well positioned across tourist destinations and vibrant markets in U.S. states and Canada.
<h3>Tanger: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Tanger's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.55% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Tanger's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 19.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Tanger's ROE stands out, surpassing industry averages. With an impressive ROE of 4.44%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tanger's ROA stands out, surpassing industry averages. With an impressive ROA of 1.07%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.79, Tanger faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Tanger

Across the recent three months, 7 analysts have shared their insights on Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $44.29, a high estimate of $55.00, and a low estimate of $28.00. This current average represents a 9.0% decrease from the previous average price target of $48.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728673280_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Sprout Social by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sprout Social. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sprout Social compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Sprout Social's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Sprout Social's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sprout Social analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Sprout Social</h2>
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. The firm generates majority revenue from software subscriptions.
<h3>Sprout Social: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sprout Social displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 25.32%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -16.99%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sprout Social's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -11.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Sprout Social's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.31%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Sprout Social's debt-to-equity ratio is below the industry average at 0.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Sprout Social: Insights From 7 Financial Analysts

Benchmark analyst Todd Brooks reiterates Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Buy and maintains $520 price target.

Benchmark Reiterates Buy on Domino's Pizza, Maintains $520 Price Target

These Healthcare stocks are trading higher:-Chromadex Corp (CDXC) stock is trading at $3.18, a gain of $0.78, or 31.67%, on high volume.  Chromadex Corp CS gets a Sentiment Score of Very Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.55.  -Akso Health G

Healthcare Stocks Moving Monday: CDXC, AHG, IMRX, ELTX, CMAX, ABEO, ZJYL, WGS

PHIO and MGRM among healthcare movers

VERI, CHEK and MESO are among pre market gainers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has regained compliance with Nasdaq's public holders r...

Jin Medical Regains Nasdaq Compliance, Aims for Timely Filing

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical Technologies Ltd. faces scrutiny as its former auditor, DNTW Toronto LLP,...

Jin Medical Auditor Resigns Amid Dispute

WIRE, CUTR and USEG are among premarket  gainers

Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has successfully regained compliance with Nasdaq's fil...

Jin Medical Regains Nasdaq Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
June may not be the first month you consider when you plan to invest, but this isn&rsquo;t a month that should be overlooked. June is an ideal time to look for A-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to diversify your portfolio and lead to some potentially lucrative returns.



Penny stocks are shares of companies with stock valued under $5. It&rsquo;s appealing to investors since they can acquire a significant stake in a company with a small investment.



However, not all penny stocks are created equal, and the risks associated with them can be substantial. This is where A-rated penny stocks come into play.



A-rated penny stocks get their rankings from the Portfolio Grader, which assigns stocks a letter grade based on earnings performance, growth, analyst sentiment and buying momentum. By keeping your eye on A-rated penny stocks, you&rsquo;re assured of getting the best of these low-priced stocks and setting yourself up for a better overall return.



And with June being a popular month for companies to file earnings reports, investors are armed with new information about these companies&rsquo; performance and outlook.



There are seven A-rated penny stocks on today&rsquo;s list, and any of them would be a solid addition to a portfolio while mitigating the risks that are commonly associated with smaller companies.



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Biotech companies can be challenging investments. Bringing a drug to market is no small feat, as it requires millions of dollars in research and development and multiple successful clinical trials before you can even consider seeking regulatory approval and achieve commercialization.



But Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) is an exception to the rule. The company is the creator of DehydraTECH, which is a drug delivery technology that improves the way active drugs enter the bloodstream.



DehydraTECH increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled tablets, capsules and oral suspensions because it can mask the taste of medications.



Biotechs can incorporate the DehydraTECH platform into any of their oral medications to make them more effective and tolerable for patients.



Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field.



The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.



At the end of the <a href="https://ir.lexariabioscience.com/financial-information/financial-results">second quarter</a>, Lexaria was in a strong cash position, with $4.7 million on hand. Revenue in the quarter was only $145,000, but that is better than the $20,000 the company received in the second fiscal quarter of 2023. The company reported a loss of $668,000, but its losses are significantly dropping as the company edges toward profitability.



LEXX stock is up 130% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>JanOne (JAN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>JanOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/jan-stock-quote/">JAN</a>) is yet another bioscience company. It is developing nonaddictive treatments for conditions that cause severe pain. Its work is dedicated to helping people manage their pain without getting hooked on a treatment and developing a dependency for a drug, such as opioids.



Its most promising drug in the pipeline is a treatment for peripheral artery disease. The drug candidate has successfully completed Phase 2A trials and is awaiting Phase 2B testing to treat the disease and the pain associated with peripheral artery disease.



In addition, JanOne has a wholly owned subsidiary called <a href="https://ir.janone.com/news-events/press-releases/detail/71/janones-subsidiary-alt5-reports-91-year-over-year">ALT5 Sigma</a>, which is a fintech company that provides next-generation blockchain powered technologies. The company processed $289 million in cryptocurrency transactions in April and May combined, which was a 91% increase from a year ago.



JanOne offers an interesting way to invest in biotech and also play the cryptocurrency space. The stock is up 333% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/ocgn1600-300x169.png" alt="Person holding smartphone with logo of US biopharmaceutical company Ocugen Inc. (OCGN) on screen in front of website. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>As a small biotech company headquartered in Pennsylvania, Ocugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/">OCGN</a>) is making its mark by developing and commercializing gene and cell therapies.



The company is also getting a nice boost on June 28 when it joins the Russell 3000 index, which measures the performance of the largest 3,000 U.S. companies. Its inclusion means that Ocugen stock will be included in exchange traded funds and products that track the Russell 3000.



Ocugen is working on a breakthrough modifier gene therapy product that might treat multiple retinal diseases with a single product. It also has several products in various phases of testing to treat eye diseases.



Ocugen showed $13.2 million in operating expenses for the first quarter and had $26.4 million of cash on hand. It posted a loss of 5 cents per share versus a loss of 8 cents per share a year ago.



Losses for small biotech companies are to be expected as it takes time and money to bring new therapies to market. But OCGN stock is one of the better penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> you can buy, as the stock is up 124% so far this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Kuke Music (KUKE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/music_1600-300x169.jpg" alt="A photo of someone writing out music on staff paper with guitars in the background."><div>Source: Kemedo/ShutterStock.com</div></div>Kuke Music (NYSE:<a href="https://investorplace.com/stock-quotes/kuke-stock-quote/">KUKE</a>) is a digital music company in China. The company is a leading provider of classical music licensing, subscriptions and smart education services in China.



The company leverages its diverse content offerings and experience in music education to provide smart music education products, including Kuke smart pianos and Kuke smart teaching systems.



The company is also the organizer of the Beijing Music Festival and is working to get into the AI music field through a <a href="https://finance.yahoo.com/news/kuke-jidou-join-forces-ai-122000084.html">partnership</a> with Shanghai Jidou Science and Technology, which will see Kuke lauch an AI music application through a digital automotive software platform that Jidou develops for more than a dozen automotive companies.



<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318325464&amp;type=HTML&amp;cdn=2794ad5ad1fb979a4aae2110f8badbd2&amp;formType=20-F&amp;dateFiled=2024-05-15&amp;cik=0001809158&amp;symbol=0001809158&amp;companyName=">Kuke and its subsidiaries</a> reported revenue in 2023 of 106.9 million Chinese yuan ($14.7 million) and a loss of 65.8 million Chinese yuan. But the AI music partnership provides a path for Kuke to turn those losses into profits.



KUKE stock is up 101% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Jin Medical (ZJYL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single-300x169.jpg" alt="A close up photo of a penny. Penny Stocks to Buy"><div>Source: Shutterstock</div></div>Jin Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) is another Chinese penny stock. The company makes and sells wheelchairs and other products for the elderly and those with disabilities.



The company operates two manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. And it has relationships with more than 40 distributors in China and distributors in 20 other regions.



The majority of the company&rsquo;s wheelchair products, which includes 30 models, are sold in China and Japan.



As a Chinese company, Jin doesn&rsquo;t report its financials as often as those based in the U.S. But its <a href="https://ir.zhjmedical.com/se%D1%81filings">most current financial report</a> for the 2023 fiscal year (ending Sept. 30, 2023), included revenue of $19.8 million, up 3% from a year ago. 



Profits of $6.7 million were up 9.5% from the 2022 fiscal year, and total net income of $2.87 million was a 6.3% improvement from the previous year.



ZJYL stock, which had its initial public offering only a year ago, is having a rough 2024. The company performed a <a href="https://investorplace.com/2024/02/why-is-jin-medical-international-zjyl-stock-moving-today/">20-for-1 stock split,</a> which brought the stock price down from $217 to roughly $13.50. However, the stock has been slipping ever since, and is down in penny stock territory.



However, I&rsquo;m expecting a rebound based on the company&rsquo;s financials, and the stock currently maintains its &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Caravelle International (CACO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600-300x169.png" alt="A hexagonal grid with different tech-related icons; Tech stocks illustration. Best Tech stocks. tech stocks trading at bargain prices"><div>Source: whiteMocca / Shutterstock</div></div>Caravelle International (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) is a global ocean technology company with headquarters in Singapore. The company has routes to 50 companies and serves more than 100 ports.



Caravelle&rsquo;s innovation lies in its work with shipping and lumber industries. The company invented a patent pending process called CO-Tech, which uses the heat from its ships&rsquo; exhaust to dry wood during transportation.



Caravelle says the process is an improvement from the lumber industry&rsquo;s practice of building and maintaining wood drying facilities and the energy required to heat the wood in those facilities.



Contrast this to the traditional wood desiccation process where lumber companies must build and maintain expensive wood drying facilities, spend money on energy to heat the wood, and emit massive amounts CO2.



The company already has a <a href="http://www.caravelleglobal.com/news-detail.html?newId=1783843089586188289">memorandum of understanding</a> with the government of Gabon to provide dried timber. If it can expand the business model to other governments, Caravelle may have a groundbreaking business on its hands.



CACO stock is up 63% this year, but is still priced at less than $1 per share. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Eco Wave Power (WAVE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1932365063-300x169.png" alt="Environmental protection, renewable, sustainable energy sources. Plant growing in the bulb concept. renewable energy stocks to buy"><div>Source: Proxima Studio / Shutterstock.com</div></div>Eco Wave Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) is a clean energy company that develops electricity from the power of ocean waves. 



If you&rsquo;ve ever been caught in a rough surf you know that even those waves can pack a punch, so imagine the power that an ocean wave can provide should we be able to harness that power and turn it into a clean source of electricity.



The company&rsquo;s floaters can be attached to human-made structures to simplify installation and maintenance. The floaters draw energy from incoming waves by converting the rising and falling motion into a clean energy generation process.



The company currently works with customers in Israel, Portugal, Los Angeles and Gibraltar, a British territory. 



While there was no revenue in the first quarter and the company sustained an operating loss of $659,000, management has high hopes that the company&rsquo;s clean energy solution will be a powerful argument for coastal cities.



WAVE stock is up 79% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-penny-stocks-to-beat-june-gloom/">7 A-Rated Penny Stocks to Beat June Gloom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Penny Stocks to Beat June Gloom

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has shown a robust financial performance in their late...

Comments

Jin Medical International

Interés en corto

Jin Medical International (NASDAQ:ZJYL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL